Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Ray who wrote (1526)	11/11/1998 10:14:00 PM
From: arnie h	Respond to of 2173

Ray: You might take a look at my post of Oct 27. The tax loss carry over is in the vicinity of $8 a share which would translate to a savings of about $3 a share for a company in the diabetes field. In addition, that outfit would get full rights to the GLP-1 work, whatever is of value in the Pramlinitide program and some $10M in cash assets beyond debt. A buy out in the $1.5 - $2 range could seem attractive. The 10Q should be coming out soon. This probably won't read very well and should knock the stock back a bit. It will be interesting to see what happens after that. Regards, Arnie